AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18691879 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 75mg/m(2) plus Paclitaxel 175mg/m(2) plus Doxorubicin 40mg/m(2)
Number of subjects: 451
Study 18691879 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin 7 AUC plus Paclitaxel 175mg/m(2)
Number of subjects: 451
Study 15975103 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril/indapamide (2.0/0.625 mg daily, increasing to 4.0/1.25 mg daily after 3 months)
Number of subjects: 11140
Study 15975103 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive gliclazide MR-based glucose control aiming for HbA1c of 6.5% or lower
Number of subjects: 11140
Study 15975103 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo for perindopril/indapamide
Number of subjects: 11140
Study 15975103 — intervention group
Group type: COMPARATOR
Intervention: Local standard therapy for glucose control
Number of subjects: 11140
Study 14703409 — intervention group
Group type: EXPERIMENTAL
Intervention: SBN‐1 injection at 1 x 10(12)VP
Number of subjects: 12
Study 14703409 — intervention group
Group type: EXPERIMENTAL
Intervention: SBN‐1 injection (all doses)
Number of subjects: 12
Study 10350103 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (CTP) 12.5 mg every 8 hours orally, from 24 hours before surgery
Number of subjects: 30
Study 10350103 — intervention group
Group type: COMPARATOR
Intervention: Control group (no captopril)
Number of subjects: 30
Study 8543204 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet concentrate
Number of subjects: 40
Study 8543204 — intervention group
Group type: COMPARATOR
Intervention: No autologous platelet concentrate (control group)
Number of subjects: 40
Study 2139284 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms recombinant DNA hepatitis B vaccine (YDV)
Number of subjects: 278
Study 2139284 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 micrograms recombinant DNA hepatitis B vaccine (YDV)
Number of subjects: 278
Study 2139284 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (not specified in detail)
Number of subjects: 278
Study 7030988 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% halcinonide cream applied once daily
Number of subjects: 343
Study 7030988 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% halcinonide cream applied three times daily
Number of subjects: 343
Study 31541768 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ HDM SLIT tablet 20,000 Japanese Allergy Unit
Number of subjects: 826
Study 31541768 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ HDM SLIT tablet 10,000 Japanese Allergy Unit
Number of subjects: 826
Study 31541768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 826
Study 31309232 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein 40 mg/kg
Number of subjects: 720
Study 31309232 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein 400 mg/kg
Number of subjects: 720
Study 31309232 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein (both doses)
Number of subjects: 720
Study 31309232 — intervention group
Group type: COMPARATOR
Intervention: Control (0 mg/kg Genistein)
Number of subjects: 720
Study 28139112 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-myofascial release program for twenty weeks
Number of subjects: 66
Study 28139112 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 66
Study 26758073 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 41
Study 26758073 — intervention group
Group type: COMPARATOR
Intervention: LMA
Number of subjects: 41
Study 25064038 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric (ECC) exercise training
Number of subjects: 0
Study 21997802 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg
Number of subjects: 39
Study 21997802 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 39
Study 19357315 — intervention group
Group type: EXPERIMENTAL
Intervention: Social cognitive theory‐based intervention (written materials and 5 weekly, 20‐ to 30‐min telephone counseling sessions)
Number of subjects: 59
Study 19357315 — intervention group
Group type: COMPARATOR
Intervention: Control condition (written materials only)
Number of subjects: 59
Study 17972459 — intervention group
Group type: EXPERIMENTAL
Intervention: S100beta
Number of subjects: 20
Study 17972459 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium (Mg)
Number of subjects: 20
Study 17972459 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between S100beta and Mg
Number of subjects: 20
Study 15614598 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip protector use
Number of subjects: 0
Study 15614598 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 11764425 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot sole pump (A-V Impulse System)
Number of subjects: 62
Study 11764425 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 62
Study 9440565 — intervention group
Group type: COMPARATOR
Intervention: Inhaled formoterol (FM), 24 microg bid, and placebo tablets (PL)
Number of subjects: 11
Study 9440565 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled formoterol (FM), 24 microg bid, and oral prednisolone (PRED), 15 mg daily
Number of subjects: 11
Study 8127991 — intervention group
Group type: EXPERIMENTAL
Intervention: Original Oucher
Number of subjects: 79
Study 8127991 — intervention group
Group type: COMPARATOR
Intervention: Reduced-size Oucher
Number of subjects: 79
Study 2672061 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 30
Study 2672061 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 30
Study 2672061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 772979 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetraolean
Number of subjects: 1672
Study 772979 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline
Number of subjects: 1672
Study 31647011 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncokompas alongside care as usual
Number of subjects: 136
Study 31647011 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (waiting list control group)
Number of subjects: 136
Study 28479368 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed maintenance therapy
Number of subjects: 0
Study 28479368 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed plus cisplatin (PC) induction therapy
Number of subjects: 0
Study 28479368 — intervention group
Group type: COMPARATOR
Intervention: 6 cycles of PC (JMDB trial)
Number of subjects: 0
Study 25956613 — intervention group
Group type: COMPARATOR
Intervention: Fenofibrate 300 mg daily
Number of subjects: 90
Study 25956613 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 300 mg daily plus pentoxifylline 1200 mg/day in three divided doses for 24 weeks
Number of subjects: 90
Study 22543064 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-controlled ventilation (VCV) with tidal volume (Vt) of 8 mL•kg(‐1) and PEEP of 0 cm H(2)O
Number of subjects: 15
Study 22543064 — intervention group
Group type: COMPARATOR
Intervention: Pressure-controlled ventilation (PCV) with tidal volume (Vt) of 8 mL•kg(‐1) and PEEP of 0 cm H(2)O
Number of subjects: 15
Study 22543064 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing PEEP from 0 to 5 cm H(2)O
Number of subjects: 15
Study 22543064 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing tidal volume (Vt)
Number of subjects: 15
Study 22543064 — intervention group
Group type: EXPERIMENTAL
Intervention: VDSCM including flow-dependent parameter
Number of subjects: 15
Study 21261438 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dissonance program
Number of subjects: 124
Study 21261438 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dissonance program
Number of subjects: 124
Study 21261438 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 124
Study 19430275 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine consultations
Number of subjects: 1
Study 19430275 — intervention group
Group type: COMPARATOR
Intervention: Telephone-only consultations
Number of subjects: 1
Study 16736620 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-point relief-tension suspension technique (Group A)
Number of subjects: 82
Study 16736620 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 82
Study 15107217 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 70
Study 15107217 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil
Number of subjects: 70
Study 11083648 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid (600 mg i.v. every 12 h)
Number of subjects: 826
Study 11083648 — intervention group
Group type: COMPARATOR
Intervention: Oxacillin-dicloxacillin (2 g i.v. every 6 h)
Number of subjects: 826
Study 11083648 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid (600 mg orally every 12 h)
Number of subjects: 826
Study 11083648 — intervention group
Group type: COMPARATOR
Intervention: Oxacillin-dicloxacillin (500 mg orally every 6 h)
Number of subjects: 826
Study 11083648 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 826
Study 11083648 — intervention group
Group type: COMPARATOR
Intervention: Oxacillin-dicloxacillin
Number of subjects: 826
Study 9543224 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil (900 mg once daily)
Number of subjects: 40
Study 9543224 — intervention group
Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 40
Study 1298571 — intervention group
Group type: EXPERIMENTAL
Intervention: Shower-based oral hygiene system (SBOHS)
Number of subjects: 84
Study 1298571 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrushing
Number of subjects: 84
Study 1298571 — intervention group
Group type: COMPARATOR
Intervention: Electric toothbrushing
Number of subjects: 84
Study 2420603 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cisplatin, vinblastine and bleomycin followed by intravenous cyclophosphamide
Number of subjects: 36
Study 2420603 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide (consolidation regimen)
Number of subjects: 36
Study 31134600 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation and auricular acupressure for six weeks
Number of subjects: 0
Study 31134600 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 30658377 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilized chlorine dioxide mouthwash (0.1%)
Number of subjects: 50
Study 30658377 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 50
Study 26679830 — intervention group
Group type: EXPERIMENTAL
Intervention: AUD$30 cash following receipt of doses two and three (incentive condition)
Number of subjects: 139
Study 26679830 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control condition)
Number of subjects: 139
Study 24632109 — intervention group
Group type: EXPERIMENTAL
Intervention: family‐based treatment
Number of subjects: 121
Study 24632109 — intervention group
Group type: EXPERIMENTAL
Intervention: individual adolescent supportive psychotherapy
Number of subjects: 121
Study 24632109 — intervention group
Group type: EXPERIMENTAL
Intervention: weight gain
Number of subjects: 121
Study 24632109 — intervention group
Group type: EXPERIMENTAL
Intervention: longer duration of illness, greater eating disorder pathology, binge‐eating/purging subtype
Number of subjects: 121
Study 23338252 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective COX‐2 inhibitor
Number of subjects: 30
Study 23338252 — intervention group
Group type: COMPARATOR
Intervention: Steroidal anti-inflammatory drug
Number of subjects: 30
Study 23338252 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 20927421 — intervention group
Group type: COMPARATOR
Intervention: One-stage putty-wash impressions
Number of subjects: 48
Study 20927421 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophase impressions
Number of subjects: 48
Study 20927421 — intervention group
Group type: COMPARATOR
Intervention: Two-stage putty-wash impressions
Number of subjects: 48
Study 18375714 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional assisted ventilation (PAV)
Number of subjects: 9
Study 18375714 — intervention group
Group type: COMPARATOR
Intervention: Sham ventilation
Number of subjects: 9
Study 15847627 — intervention group
Group type: EXPERIMENTAL
Intervention: Harm minimization intervention (eight 1-hour lessons over 2 years, quitting support from school nurses, enactment of supportive policies)
Number of subjects: 4000
Study 15847627 — intervention group
Group type: EXPERIMENTAL
Intervention: Harm minimization intervention
Number of subjects: 4000
Study 15847627 — intervention group
Group type: COMPARATOR
Intervention: Standard abstinence-based programme
Number of subjects: 4000
Study 12419715 — intervention group
Group type: EXPERIMENTAL
Intervention: Three minutes of supramaximal stimulation (0.1 Hz, 20 mA) before mivacurium 0.2 mg.kg(‐1)
Number of subjects: 20
Study 12419715 — intervention group
Group type: EXPERIMENTAL
Intervention: Ten minutes of supramaximal stimulation (0.1 Hz, 20 mA) before mivacurium 0.2 mg.kg(‐1)
Number of subjects: 20
Study 12419715 — intervention group
Group type: EXPERIMENTAL
Intervention: Three minutes of supramaximal stimulation measured by AMG
Number of subjects: 20
Study 12419715 — intervention group
Group type: EXPERIMENTAL
Intervention: Ten minutes of supramaximal stimulation measured by AMG
Number of subjects: 20
Study 12419715 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PMG and AMG
Number of subjects: 20
Study 11153926 — intervention group
Group type: EXPERIMENTAL
Intervention: Chelating agent (DMPS)
Number of subjects: 120
Study 11153926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 9195520 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 35
Study 9195520 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 35
Study 9195520 — intervention group
Group type: COMPARATOR
Intervention: Ketoprofen
Number of subjects: 35
Study 9195520 — intervention group
Group type: COMPARATOR
Intervention: Sulindac
Number of subjects: 35
Study 8244121 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 289
Study 8244121 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg
Number of subjects: 289
Study 8244121 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg
Number of subjects: 289
Study 4033539 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (1.2 mg/kg/day for 70 days)
Number of subjects: 32
Study 4033539 — intervention group
Group type: COMPARATOR
Intervention: Prednisone with alkylating agents
Number of subjects: 32
Study 4033539 — intervention group
Group type: COMPARATOR
Intervention: Alkylating agent alone
Number of subjects: 32
Study 30390523 — intervention group
Group type: EXPERIMENTAL
Intervention: Androsta‐4,16,‐dien‐3‐one (androstadienone)
Number of subjects: 0
Study 30390523 — intervention group
Group type: EXPERIMENTAL
Intervention: Estra‐1,3,5(10),16‐tetraen‐3‐ol (estratetraenol)
Number of subjects: 0
Study 29720379 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigger point dry needling (TrP‐DN)
Number of subjects: 56
Study 29720379 — intervention group
Group type: COMPARATOR
Intervention: Placebo needling
Number of subjects: 56
Study 29720379 — intervention group
Group type: COMPARATOR
Intervention: No treatment (untreated control group)
Number of subjects: 56
Study 27676085 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral extended-release calcifediol (30 or 60 µg) once daily at bedtime for 26 weeks
Number of subjects: 429
Study 27676085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429
Study 24030517 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial programme (CP)
Number of subjects: 772
Study 24030517 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 772
Study 22264653 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil + exercise
Number of subjects: 9
Study 22264653 — intervention group
Group type: COMPARATOR
Intervention: Butter + no exercise
Number of subjects: 9
Study 22264653 — intervention group
Group type: COMPARATOR
Intervention: Olive oil + no exercise
Number of subjects: 9
Study 22264653 — intervention group
Group type: COMPARATOR
Intervention: Butter + exercise
Number of subjects: 9
Study 20141260 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention to nonthreatening words and text while ignoring worry-related material
Number of subjects: 0
Study 20141260 — intervention group
Group type: COMPARATOR
Intervention: Mixed-attention control condition
Number of subjects: 0
Study 18277062 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate distant healing for 6 months
Number of subjects: 409
Study 18277062 — intervention group
Group type: COMPARATOR
Intervention: Deferred distant healing (waiting for 6 months)
Number of subjects: 409
Study 18277062 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinding (unblinded patients)
Number of subjects: 409
Study 15886057 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardibra (treatment group)
Number of subjects: 20
Study 15886057 — intervention group
Group type: COMPARATOR
Intervention: Regular bra (control group)
Number of subjects: 20
Study 12642846 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg once daily
Number of subjects: 676
Study 12642846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 676
Study 10384914 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrademal injections of 100 microg/ml compound 48/80
Number of subjects: 0
Study 10384914 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% capsaicin cream
Number of subjects: 0
Study 10384914 — intervention group
Group type: COMPARATOR
Intervention: Control group (bullous pemphigoid, herpes zoster, insect bullous eruption)
Number of subjects: 0
Study 10384914 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheal reaction induced immediately before suction blistering
Number of subjects: 0
Study 8882821 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed rotational angioplasty after primary guidewire recanalization
Number of subjects: 124
Study 8882821 — intervention group
Group type: COMPARATOR
Intervention: Sequential PTCA
Number of subjects: 124
Study 28685934 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/d for 6 weeks
Number of subjects: 26
Study 28685934 — intervention group
Group type: COMPARATOR
Intervention: RAAS inhibition
Number of subjects: 26
Study 27496788 — intervention group
Group type: EXPERIMENTAL
Intervention: Wholegrain pasta (WGP)
Number of subjects: 16
Study 27496788 — intervention group
Group type: COMPARATOR
Intervention: Refined grain pasta (RGP)
Number of subjects: 16
Study 24990161 — intervention group
Group type: EXPERIMENTAL
Intervention: Rikkunshito (RKT) combined with rabeprazole (RPZ) 10 mg/q.d. for 8 weeks
Number of subjects: 95
Study 24990161 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) combined with rabeprazole (RPZ) 10 mg/q.d. for 8 weeks
Number of subjects: 95
Study 24990161 — intervention group
Group type: EXPERIMENTAL
Intervention: Rikkunshito (RKT)
Number of subjects: 95
Study 22883036 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine infusion (loading dose 100 µg/kg followed by continuous infusion 10 µg/(kg·h) for 70.05 ± 29.05 h)
Number of subjects: 46
Study 22883036 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine infusion
Number of subjects: 46
Study 22883036 — intervention group
Group type: COMPARATOR
Intervention: 5% glucose infusion (control group)
Number of subjects: 46
Study 21605286 — intervention group
Group type: EXPERIMENTAL
Intervention: full-mouth disinfection
Number of subjects: 54
Study 21605286 — intervention group
Group type: EXPERIMENTAL
Intervention: full-mouth scaling and root planing
Number of subjects: 54
Study 21605286 — intervention group
Group type: EXPERIMENTAL
Intervention: scaling and root planing within 7 days
Number of subjects: 54
Study 21605286 — intervention group
Group type: COMPARATOR
Intervention: initial carious lesions
Number of subjects: 54
Study 21605286 — intervention group
Group type: COMPARATOR
Intervention: sound surfaces
Number of subjects: 54
Study 17398372 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg simvastatin daily
Number of subjects: 20536
Study 17398372 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 20536
Study 15642701 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 10
Study 12095189 — intervention group
Group type: EXPERIMENTAL
Intervention: High narcissism with low self-concept clarity
Number of subjects: 0
Study 12095189 — intervention group
Group type: EXPERIMENTAL
Intervention: Less narcissistic individuals with high self-concept clarity
Number of subjects: 0
Study 12095189 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger and depression
Number of subjects: 0
Study 10786531 — intervention group
Group type: EXPERIMENTAL
Intervention: Education programme on how to use and take care of a PIV; details on dosage and duration not available.
Number of subjects: 36
Study 10786531 — intervention group
Group type: COMPARATOR
Intervention: Current routines followed by nurses in the control group; details on dosage and duration not available.
Number of subjects: 36
Study 8647062 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrilon Pept
Number of subjects: 79
Study 8647062 — intervention group
Group type: EXPERIMENTAL
Intervention: Pepti Junior
Number of subjects: 79
Study 1972313 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldactazine alone (altizide + spironolactone, 2 tablets per day)
Number of subjects: 780
Study 1972313 — intervention group
Group type: COMPARATOR
Intervention: Aldactazine plus a conventional antihypertensive agent (1 or 2 tablets per day)
Number of subjects: 780
Study 116856 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (CL) 2 x 75 microgram/day for 2 weeks
Number of subjects: 60
Study 116856 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (CL)
Number of subjects: 60
Study 31830014 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 0
Study 31830014 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (control)
Number of subjects: 0
Study 28692531 — intervention group
Group type: EXPERIMENTAL
Intervention: EFV-based ART
Number of subjects: 60